11.24.15
Purdue Pharma has appointed Alan Dunton to the position of senior vice president of research and development. In this role, Dr. Dunton will serve as the company’s lead scientist and will oversee the medical research and drug safety, clinical pharmacology, virtual discovery, and pharmaceutics and analytics teams.
“At a time of transformation for Purdue, Alan brings the right skills and experience to diversify and grow our portfolio,” said Mark Timney, chief executive officer, Purdue Pharma. “We look forward to his contributions in optimizing our existing pipeline, while strengthening our presence in other therapeutic areas.”
Dr. Dunton will be responsible for spearheading the company’s overall scientific development strategy, including management of the pipeline, early clinical development programs, and setting the scientific direction for the company.
Dr. Dunton has devoted his 33-year career to the discovery and development of new prescription and over-the-counter (OTC) drug products. In 2006, he founded Danerius LLC, a biotechnology and pharmaceutical consulting business, which he led until joining Purdue.
“At a time of transformation for Purdue, Alan brings the right skills and experience to diversify and grow our portfolio,” said Mark Timney, chief executive officer, Purdue Pharma. “We look forward to his contributions in optimizing our existing pipeline, while strengthening our presence in other therapeutic areas.”
Dr. Dunton will be responsible for spearheading the company’s overall scientific development strategy, including management of the pipeline, early clinical development programs, and setting the scientific direction for the company.
Dr. Dunton has devoted his 33-year career to the discovery and development of new prescription and over-the-counter (OTC) drug products. In 2006, he founded Danerius LLC, a biotechnology and pharmaceutical consulting business, which he led until joining Purdue.